RCT comparing ivermectin + SOC vs. HCQ + SOC, showing a significant reduction in mortality with ivermectin. Mortality relative risk:
RR 0.11, p
= 0.12 (mild/moderate cases)
RR 0.1, p
< 0.001 (severe cases)
The HCQ dose is relatively low and may be too low to reach therapeutic levels. This paper also reports a prophylaxis study .
Elgazzar et al., 11/13/2020, Randomized Controlled Trial, Egypt, Africa, preprint, 6 authors, dosage 400μg/kg days 1-4, this trial compares with another treatment - results may be better when compared to placebo.
risk of death, 91.7% lower, RR 0.08, p < 0.001, treatment 2 of 200 (1.0%), control 24 of 200 (12.0%).
risk of death, 88.9% lower, RR 0.11, p = 0.12, treatment 0 of 100 (0.0%), control 4 of 100 (4.0%), continuity correction due to zero event (with reciprocal of the contrasting arm), mild/moderate COVID-19.
risk of death, 90.0% lower, RR 0.10, p < 0.001, treatment 2 of 100 (2.0%), control 20 of 100 (20.0%), severe COVID-19.
Effect extraction follows pre-specified rules prioritizing more serious
outcomes. For an individual study the most serious outcome may have a smaller
number of events and lower statistical signficance, however this provides the
strongest evidence for the most serious outcomes when combining the results of